Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Bio-Path Stock Down 2.9 %

NASDAQ BPTH opened at $0.95 on Friday. Bio-Path has a 52 week low of $0.59 and a 52 week high of $11.58. The firm’s 50-day simple moving average is $0.90 and its two-hundred day simple moving average is $1.18.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission (SEC). 5.74% of the stock is owned by hedge funds and other institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.